3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Neoplasms
14
Venous Thromboembolism
11
Venous Thrombosis
4
Thrombosis
3
Pulmonary Embolism
3
Multiple Myeloma
3
Upper Extremity Deep Vein Thrombosis
2
Lung Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thromboembolism
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Prevention of Venous Thromboembolism
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia
1
Inflammation
1
Immune System Diseases
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Interventions
Gemcitabine
82
Cisplatin
52
Oxaliplatin
36
lenvatinib
24
durvalumab
22
Capecitabine
22
Fluorouracil
20
Leucovorin
15
tislelizumab
11
pembrolizumab
10
apatinib
10
Radiotherapy
10
Albumin-Bound Paclitaxel
10
Radiofrequency Ablation
9
Magnetic Resonance Spectroscopy
9
Irinotecan
9
Floxuridine
9
Liver Transplantation
8
Drug Therapy
8
Cholangiopancreatography, Endoscopic Retrograde
8
130-nm albumin-bound paclitaxel
8
Taxes
7
Platinum
7
Photochemotherapy
7
Panitumumab
7
Biopsy
7
1,2-diaminocyclohexaneplatinum II citrate
7
tremelimumab
6
pemigatinib
6
camrelizumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cholangiocarcinoma
×
Rivaroxaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled